Director Maurice Ferré resigns from MedTech board; Aguero appointed to committees

TriSalus Life Sciences, Inc.

Maurice R. Ferré resigned as director and all positions on Feb 19, 2022; no disagreement with the company.
Manuel Aguero appointed to the Audit and Compensation committees effective upon Ferré's resignation.
Ferré remains Chairman of Memic Innovative Surgery, the target in MedTech's proposed business combination.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Maurice R. Ferré

Director

TLSI · TriSalus Life Sciences, Inc.

Effective: 2022-02-19
Filed: February 23, 2022, 6:59 PM ET

On February 19 2022, Maurice R. Ferré, MD notified MedTech Acquisition Corporation (“MedTech” or the “Company”) that he was resigning as a member of the Company’s Board of Directors and all other positions with the Company effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Maurice R. Ferré resigned as Director at TriSalus Life Sciences, Inc..

Action: resigned
Role: Director

Exact text from the filing

On February 19 2022, Maurice R. Ferré, MD notified MedTech Acquisition Corporation (“MedTech” or the “Company”) that he was resigning as a member of the Company’s Board of Directors and all other positions with the Company effective immediately.

View on SEC.gov

TriSalus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-026153

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.